N. Bardy-Bouxin

发表

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, American journal of hematology.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

G. Devgan, M. Woloj, E. Matczak, 2015, Biologics : targets & therapy.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

M. Campone, S. Isakoff, E. Leip, 2014, British Journal of Cancer.

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

U. Olsson‐Strömberg, T. Brümmendorf, S. Schmidt, 2020, Leukemia.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2018, Haematologica.

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Wolfgang Eiermann, Fatima Cardoso, W. Eiermann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

M. Borad, A. Daud, W. Messersmith, 2011, Clinical Cancer Research.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, L. Chow, P. Goss, 2014, The oncologist.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

M. Baccarani, H. Kantarjian, G. Martinelli, 2007 .

Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML)

T. Brümmendorf, G. Rosti, B. Smith, 2019, Clinical Lymphoma Myeloma and Leukemia.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, P. Goss, Bing-he Xu, 2014, The oncologist.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012 .

Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015 .

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).

U. Olsson‐Strömberg, T. Brümmendorf, G. Rosti, 2019, Journal of Clinical Oncology.